Evidence map›Paper›PMID 33408764›Full record

ArticleTheranostics2021

Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.

Yvonne H W Derks, Mark Rijpkema, Helene I V Amatdjais-Groenen, Annemarie Kip, Gerben M Franssen, J P Michiel Sedelaar, Diederik M Somford, Michiel Simons, Peter Laverman, Martin Gotthardt and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Review
  6. Lessons learned in application driven imaging agent design for image-guided surgery.European journal of nuclear medicine and molecular imaging · 2024
    Review
  7. Review
  8. Article
  9. Article
  10. Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.European journal of nuclear medicine and molecular imaging · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. European journal of nuclear medicine and molecular imaging · 2022
    Article
  18. Article
  19. Review
  20. Advances in PSMA-targeted therapy for prostate cancer.Prostate cancer and prostatic diseases · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Yvonne H W DerksDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Mark RijpkemaDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Helene I V Amatdjais-GroenenRadboud University Nijmegen, Institute for Molecules and Materials, Systems Chemistry, Nijmegen, The Netherlands.
Annemarie KipDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Gerben M FranssenDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
J P Michiel SedelaarDepartment of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Diederik M SomfordProsper Clinics, Nijmegen, The Netherlands.
Michiel SimonsDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Peter LavermanDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Martin GotthardtDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Dennis W P M LöwikRadboud University Nijmegen, Institute for Molecules and Materials, Systems Chemistry, Nijmegen, The Netherlands.
Susanne LütjeDepartment of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Sandra HeskampDepartment of Medical Imaging, Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
Radboud University Nijmegen · NLCanisius-Wilhelmina Ziekenhuis · NLUniversity Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incomplete resection of prostate cancer (PCa) occurs in 15%-50% of PCa patients. Disease recurrence negatively impacts oncological outcome. The use of radio-, fluorescent-, or photosensitizer-labeled ligands to target the prostate-specific membrane antigen (PSMA) has become a well-established method for the detection and treatment of PCa.

Indexed as

AnimalsAntigens, SurfaceApoptosisCell ProliferationGlutamate Carboxypeptidase IIHumansLigandsMaleMiceMice, Inbred BALB CMice, NudePhotosensitizing AgentsPrognosisProstatectomyProstatic NeoplasmsRadiopharmaceuticalsAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILigandsPhotosensitizing AgentsRadiopharmaceuticalsimaging agentsintraoperativeprostate cancerProstate-specific membrane antigenradiochemistry

Identifiers

PMID33408764
PMCPMC7778589
OpenAlexW3111900304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.